VOLUME 287 (2012) PAGES 5615–5626
PAGE 5620:
In this article, the authors have inadvertently used MTA1-siRNA and control β- actin panels from other project while reprobing the same membrane for RNF144A antibody used in panel C. This change does not alter the conclusion as well as the quantification of the RNF144 protein of this study. The revised figure and figure legend are presented below.
FIGURE 3.
MTA1 negatively regulates RNF144A expression at mRNA level. A and B, Western blot analysis of the protein extracts from MCF-7 cells stably expressing pcDNA empty vector (MCF-7/pcDNA) and T7-MTA1 (MCF-7/T7-MTA1) with the indicated antibodies (A) and quantitative results of Western blots (B) using ImageJ software. C, HeLa cells were transfected with control siRNAs or specific siRNAs targeting human MTA1. After 48 h of the second round of transfection, protein extracts were prepared and subjected to Western blot analysis with anti-RNF144A antibody. D, quantitative result of Western blot of RNF144A in panel C using ImageJ software. E and F, qRT-PCR analysis of the expression of RNF144A and MTA1 mRNA levels in the MCF-7/pcDNA and MCF-7/T7-MTA1 stable clone cells (E) and HeLa cells transfected with control siRNAs or specific siRNAs targeting human MTA1 (F). G, MCF-7 cells were transfected with control siRNAs or specific siRNAs targeting human MTA1. After 36 h of the second round of transfection, cells were treated with or without 250 ng/ml of actinomycin D (Act-D) for another 12 h and then subjected to qRT-PCR analysis of the expression of RNF144A and MTA1 mRNA levels as described above. DMSO, dimethyl sulfoxide.